Myeloid and Monocytic Leukemia, Phase II
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
Volunteers
Health Professionals
What is the purpose of this trial?
Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alexis Walker, PA
- Armand Russo, MD
- Catherine Wei, MD
- Clarice Grens, APRN
- D. Barry Boyd, MD, MS
- Daniel Boxer, MD
- Elan Gorshein, DO, JD, MPH
- Elizabeth Gaa, APRN
- Emily Kopas, APRN, OCN
- Ethan Kohn, PA
- Francesca Montanari, MD
- Francine Foss, MD
- Iris Isufi, MD
- Jadwiga Kretowicz, APRN
- Jean Vollmer, APRN
- Johanna LaSala, MD
- Jose Morales-Marin
- Justine Boulanger-Parzych, APRN
- Kayla Martello
- Kristen Hoxie, PA
- Larisa Fleysher, APRN
- Laura Sabourin
- M. Sung Lee, MD
- Madeline Santiago
- Osarugue Otasowie
- Sara Anastasio, APRN, RN
- Sarah Carlson, PA
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Syed Ali
- Vidya Kesavan
- Virginia Syombathy, APRN
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Last Updated05/17/2026
- Study IRB#2000037447